Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + everolimus
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alpelisib + everolimus is a combination therapy targeting the PI3K/AKT/mTORC1 signaling pathway. Alpelisib is a selective inhibitor of the phosphatidylinositol 3-kinase (PI3K) alpha subunit (p110α), while everolimus is an mTORC1 (mechanistic target of rapamycin complex 1) inhibitor. This combination provides synergistic efficacy by simultaneously blocking two critical points in the PI3K/AKT/mTORC1 pathway, which is implicated in cancer progression and resistance to anti-estrogen treatments.
02
Targets
Mechanistic target of rapamycin complex 1PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on alpelisib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + everolimus.